RT Journal Article
SR Electronic
T1 Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.14.24308948
DO 10.1101/2024.06.14.24308948
A1 Baum, Holly E.
A1 Santopaolo, Marianna
A1 Francis, Ore
A1 Milowdowski, Emily
A1 Entwistle, Katrina
A1 Oliver, Elizabeth
A1 Hitchings, Benjamin
A1 Diamond, Divya
A1 Thomas, Amy C.
A1 Mitchell, Ruth E.
A1 Kibble, Milla
A1 Gupta, Kapil
A1 Di Bartolo, Natalie
A1 Klenerman, Paul
A1 Brown, Anthony
A1 Morales-Aza, Begonia
A1 Oliver, Jennifer
A1 Berger, Imre
A1 Toye, Ash M.
A1 Finn, Adam
A1 Goenka, Anu
A1 Davidson, Andrew D.
A1 Ring, Susan
A1 Molloy, Lynn
A1 Lewcock, Melanie
A1 Northstone, Kate
A1 Roth, Firona
A1 Timpson, Nicholas J.
A1 Wooldridge, Linda
A1 Halliday, Alice
A1 Rivino, Laura
YR 2024
UL http://medrxiv.org/content/early/2024/08/08/2024.06.14.24308948.abstract
AB Immunological memory to vaccination and viral infection involves coordinated action of B and T-cells, thus integrated analysis of these two components is critical for understanding their contributions to protection against breakthrough infections (BI). We investigated cellular and humoral immune responses to SARS-CoV-2 infection and/or COVID-19 vaccination in participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). The magnitude of antibody and T-cell responses following the second vaccine dose was associated with protection against BI in participants with a history of SARS-CoV-2 infection (cases), but not in infection-naïve controls. Youden’s index thresholds for protection against BI were calculated for all immune measures. Anti-Spike IgG (>666.4 BAU/mL) and anti-Nucleocapsid pan Ig (>0.1332 BAU/mL) thresholds combined were 100% specific and 83.3% sensitive for cases without BI over 8-months follow-up. Collectively these results point to the superior protective effect of hybrid immunity and have implications for the design of next-generation COVID-19 vaccines.Competing Interest StatementAF was a lead investigator on trials of COVID-19 vaccines funded by Oxford/Astra-Zeneca, Valneva and Sanofi and the UK government. He also leads a University of Bristol sponsored epidemiological study of adult respiratory disease funded by Pfizer which has evaluated COVID-19 vaccine effectiveness. During the pandemic he was a member of the Joint Committee on Vaccination and Immunisation which advised the UK government on COVID-19 vaccine policy and of the WHO Specialist Advisory Group of Experts COVID-19 vaccine working group. No other authors declare competing interests. Funding StatementThis work was funded by UK Research and Innovation (UKRI) and the National Institute of Health Research (NIHR) through the UK COVID-19 Immunology Consortium (UK CIC). This work was supported by the Elizabeth Blackwell Institute, University of Bristol, with funding from the Wellcome Trust ISSF3 grant 204813/Z/16/Z, and the University Alumni and Friends (LW, LR, AH, AD, AF and OF). NJT is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). MK is supported by the Medical Research Council (MR/W021315/1). MS is supported by the Academy of Medical Sciences (Springboard Award SB007\100173). The UK Medical Research Council and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors; LR, AH, LW, HEB and MS will serve as guarantors for the contents of this paper. A comprehensive list of grant funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). This research was specifically funded by Wellcome Trust and MRC grant 102215/2/13/2. The funders had no role in the study design, data collection, data analysis nor preparation of the manuscript or decision to publish. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ALSPAC Ethics and Law Committee at the University of Bristol gave ethical approval for this work (NHS REC 20/HRA/4854). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.